Skip to Late-Breaking Abstracts »
All accepted abstracts will be available in the Journal for ImmunoTherapy of Cancer (JITC).
Onsite posters will be presented in the Poster Hall at the Walter E. Washington Convention Center in Washington, D.C. All odd numbered posters will be presented on Friday, Nov. 12, 2021. Even numbered posters will be presented Saturday, Nov. 13, 2021.
ePosters will be on display on the SITC 2021 virtual meeting platform from 7 a.m. EST on Friday, Nov. 12, 2021 until the virtual meeting platform is closed on Jan. 9, 2022.
# | Type | Title | Authors | Category | Keywords |
---|---|---|---|---|---|
90 | Poster Presentation | Unbiased proteomic profiling leads to the discovery of a novel non-invasive blood-based protein panel with significant positive predictive value in pancreatic and colorectal cancers | Kristina Beeler, Dr.; Roland Bruderer, PhD; Marco Tognetti, PhD; Kamil Sklodowski, PhD; Sebastian Mueller, PhD; Dominique Kamber; Lukas Reiter, PhD | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers;Proteomics;Solid tumors |
343 | Poster Presentation | Multiomic biomarker signatures identify subsets of patients who may benefit from either nivolumab or sotigalimab in combination with chemotherapy in metastatic pancreatic cancer. | Deena M. Maurer, PhD; Jia Xin Yu, PhD; Kamil Sklodowski, PhD; Marco Tognetti, PhD; Lukas Reiter, PhD; Roland Bruderer, PhD; Jakob Vowinckel, PhD; Shannon M. Pfeiffer, MS; Mark H. O'Hara, MD; Eileen M. O’Reilly, MD; Robert A. Wolff, MD; Zev A. Wainberg, MD; Andrew H. Ko, MD; Osama Rahm, MD; George A. Fisher, MD; Jaclyn P. Lyman, MS; Christopher R. Cabanski, PhD; Pier Federico Gherardini, PhD; Jill O’Donnell-Tormey, PhD; Theresa M. LaVallee, PhD; Robert H. Vonderheide, MD, PhD; Lacey J. Kitch, PhD | Clinical Trials Completed | Biomarkers;Checkpoint blockade;Chemokine;Chemotherapy;Clinical trial;Costimulation;Immune suppression;Solid tumors |